Optimizing Process Development Early – A Critical Factor in Successful Viral Vector Scale Up and Large Scale Manufacture

Please click here to be taken to the external linkDownload

News & Press Releases

Press Release

September 3, 2025

Andelyn Biosciences and Tern Therapeutics Partner for Late-Stage Process Performance Qualification (PPQ) Manufacturing of AAV Gene Therapy for the Treatment of CLN2 Batten DiseaseAndelyn Biosciences and Tern Therapeutics Partner for Late-Stage Process Performance Qualification (PPQ) Manufacturing of AAV Gene Therapy for the Treatment of CLN2 Batten Disease
Press Release

August 21, 2025

Andelyn Biosciences and Amplo Biotechnology Partner to Manufacture Novel Gene Therapies for Diseases Affecting the Neuromuscular JunctionAndelyn Biosciences and Amplo Biotechnology Partner to Manufacture Novel Gene Therapies for Diseases Affecting the Neuromuscular Junction

May 12, 2025

Andelyn Biosciences Applies the AAV Curator® Platform to Deliver Novel Gene Therapy for an Ultra-Rare NEDAMSS Disease Patient 14-Months after DiagnosisAndelyn Biosciences Applies the AAV Curator® Platform to Deliver Novel Gene Therapy for an Ultra-Rare NEDAMSS Disease Patient 14-Months after Diagnosis
Press Release

May 6, 2025

Andelyn Biosciences AAV Curator® Platform Used to Manufacture Clinical Grade Viral Vector for FDA-Authorized First-In-World Universal Donor CRISPR/AAV Transduced CAR-NK Cells.Andelyn Biosciences AAV Curator® Platform Used to Manufacture Clinical Grade Viral Vector for FDA-Authorized First-In-World Universal Donor CRISPR/AAV Transduced CAR-NK Cells.
View All News & Press Releases
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
PreferencesDenyAccept